ArticleFrontiers in cardiovascular medicine2025
Evaluation of the prognosis of elderly patients with heart failure by Monocyte-to-High-Density Lipoprotein Ratio, Neutrophil Gelatinase-Associated Lipocalin, and Angiotensin II.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this research was to investigate the correlation between the Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR), Neutrophil gelatinase-associated lipocalin (NGAL), and Angiotensin II (Ang II) with both short-term and long-term mortality rates in elderly patients with heart failure (HF). Methods: A retrospective cohort study was conducted, encompassing elderly HF patients hospitalized from 2020 to 2023. Multivariable logistic regression analysis was employed to assess the relationship between MHR, NGAL, Ang II, and mortality risk. Results: The predictive power of these biomarkers for mortality in patients with HF was determined using the area under the receiver operating characteristic curve (AUC). Each of the biomarkers-MHR, NGAL, and Ang II-was linked to an increased risk of mortality at one month (OR = 1.007, 95% CI: 1.003-1.012), (OR = 1.004, 95% CI: 1.001-1.007), (OR = 1.002, 95% CI: 1.001-1.004) and at one year (OR = 1.007, 95% CI: 1.002-1.011), (OR = 1.004, 95% CI: 1.001-1.008), (OR = 1.003, 95% CI: 1.001-1.006) in the elderly patients with HF. The AUC for MHR, NGAL, and Ang II in forecasting one-month mortality were 0.740 (95% CI: 0.668-0.811), 0.659 (95% CI: 0.581-0.738), and 0.628 (95% CI: 0.547-0.710), respectively. For one-year mortality, the AUC values were 0.728 (95% CI: 0.655-0.800), 0.641 (95% CI: 0.560-0.721), and 0.627 (95% CI: 0.546-0.708), respectively. The optimal thresholds for MHR, NGAL, and Ang II in predicting one-month mortality were identified as 0.52, 85 ng/ml, and 25 pg/ml, respectively, while for one-year mortality, the thresholds were 0.50, 70 ng/ml, and 24 pg/ml, respectively. Conclusions: MHR, NGAL, and Ang II emerge as promising indicators for mortality prediction in HF patients. Among these, MHR stands out as potentially the most reliable predictor of mortality in the elderly with HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.